Market Overview Allergy plays a significant role in patients with atopic dermatitis. The disease mostly flares up when the patient is around things that cause allergic reactions. It is particularly common in infants as well as children and is estimated to account for about 10-20% for those having eczema, as mentioned under the American College of Allergy, Asthma & Immunology. Food allergy has been essentially highly debatable for decades in atopic dermatitis, with some common food, including milk, egg, and soy. There is a lot of literature which provides evidence that common food exacerbate atopic dermatitis. The malfunction in the immune system of the human body due to asthma is also among the major causes for atopic dermatitis. In addition, skin irritants also occur because of certain soaps, detergents, perfumes etc. Thus, the allergic reactions particularly due to food is one major factor increasing the burden of atopic dermatitis and driving this market. Other factors driving this market is the rich pipeline portfolio with products in advanced stages of clinical development, increasing government funds to support research for this disease, and rising campaigns to raise eczema awareness.
Scope of the Report Atopic dermatitis, also known as atopic eczema, often related as just a ‘skin condition’ is a misconception, which people think can be dealt with on their own. However, it impacts the patient’s life physically and emotionally. Its market mostly consists of topical treatment, steroids, and calcineurin inhibitors, primarily driven by the increasing burden of allergic reactions, including food allergy, rising campaigns for awareness, as well as high R&D in this field. The regional analysis demonstrated North America to be a dominant market for atopic dermatitis, primarily owing to higher treatment awareness among the target population, early adoption of novel medications, and better reimbursement policies.
Key Market Trends Corticosteroids Segment Dominated the Overall market by drug class
Corticosteroids are referred to as cortisone-like medicines that are used as pain relief medication for inflammation in the body. These drugs are known to have effects, such as reduced itching, swelling, allergic reactions, and redness. In addition, these drugs are use as the first line treatment for different diseases, such as skin problems, severe allergies, arthritis, and asthma. Around 30 corticosteriod compunds have been licensed for atopic dermatitis treatment of which Hydrocortisone is considered to be the first. The rising innovations have led to the advent of counterfeit medicines and alternative drugs such as immuno-modulators pimecrolimus, and tacrolimus. However, these alternatives have pitfalls, such as selective effectiveness and high cost. Hence, topical corticosteroids play a vital role in the atopic dermatitis treatment.
North America captured the largest market share and is expected to retain its dominance
North America is expected to provide high business for the atopic dermatitis market, over the forecast period, 2019-2024. The factors, such as high treatment awareness among the patient population across the United States and Canada, healthcare infrastructure, early adoption of novel medications, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations in the emerging markets help the lucrative nature of this market in North America. Though both countries deal with heavy healthcare expenditure, there are an increasing number of campaigns organized each year by certain foundations, such as the PAN Foundation, National Eczema Associations, and pharmaceutical companies along with grants.
Competitive Landscape The presence of major market players, such as Pfizer, F Hoffmann-La Roche, Allergan, Novartis, and Bayer AG, is increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies. They are also collaborating with successful personalities, initiatives, or programs at the national levels, which promote their product, and are, thus, recognized earlier than other brands in the market.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - Report customization as per the client’s requirements - 3 months of analyst support
Our reports have been used by over 10K customers, including:
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029
Summary
Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
Anatomic pathology market to register a CAGR of 7.1% from 2020 to 2025. The global anatomic pathology market size is projected to reach a value of USD 46.8 billion by 2025 from USD 33.3 billion in 2020, at a CAGR of 7.1% during the forecast period. The growth in this market is attributed to the high incidence of cancer...
Market Overview
The anti-venom market is expected to register a CAGR of nearly 4.7% during the forecast period, 2019-2024.
- Snakebite is a neglected public health issue in many tropical and subtropical countries. About 5 million snake bites occur each year, resulting in up to 2.5 million envenoming’s (poisoning...
With a population of more than 1 billion, China is the world’s largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro...
95 pages •
By Infiniti Research Limited
• Feb 2017
About Anatomic Pathology Testing
The anatomic pathology testing helps in identifying abnormalities in tissue or cell lines and develops personalized care treatment. It helps to evaluate different types of cancers such as lung cancer, breast cancer, colorectal cancer, and chronic conditions such as kidney or liver disease, infectious...
The intravascular temperature management market is expected to register a CAGR of 3.6% during the next five years. The intravascular temperature management market is expected to register a CAGR of 3.6% to reach USD 272.3 million by 2022 from USD 228.4 million in 2017. Market growth can be attributed the large number of...
Intensive Care
Pathology
Heart Attack
Europe
World
APAC
Health Expenditure
Hospital Admission
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.
